Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$6.46 USD
+0.34 (5.56%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.50 +0.04 (0.62%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BDTX 6.46 +0.34(5.56%)
Will BDTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDTX
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
BDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for BDTX
Small-cap and mid-cap Health Care has room to rally - Roth MKM
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Eyes on Walmart earnings, the July CPI print, and 13F filings
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Wedbush Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)